EL
$2.26
+0.01
(+0.22%)
As of Oct 21, 2026, 4:29 PM EDT
Price history
Eledon Pharmaceuticals Inc (ELDN) is trading up at $2.26 (+0.22%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Eledon Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | — | — | — | — | — | — | — | — | — |
| Operating income | −$5.13M | −$13.1M | −$14.1M | −$16.1M | −$18.5M | −$36.9M | −$88.4M | −$43.0M | — | — |
| Net income | −$5.66M | −$13.1M | −$14.1M | −$16.0M | −$22.8M | −$34.5M | −$88.0M | −$116.5M | −$36.2M | −$45.6M |
| EPS (diluted) | −$2.46 | −$2.30 | −$1.56 | −$24.42 | −$15.72 | −$2.33 | −$6.16 | −$4.73 | −$0.66 | −$0.52 |
| Balance sheet | ||||||||||
| Cash and equivalents | $1.10M | $17.2M | $13.0M | $8.79M | $114.2M | $84.8M | $56.4M | $4.61M | $20.5M | $22.8M |
| Total assets | $1.20M | $20.9M | $17.0M | $10.9M | $197.2M | $170.5M | $92.8M | $89.1M | $177.4M | $169.0M |
| Total liabilities | $3.90M | $1.44M | $2.53M | $1.47M | $6.59M | $6.55M | $8.61M | $81.9M | $59.3M | $32.2M |
| Shareholders' equity | −$2.70M | $19.5M | $14.5M | $9.46M | $190.6M | $164.0M | $23.8M | −$48.5M | $62.4M | $81.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$4.92M | −$14.9M | −$11.9M | −$13.9M | −$15.2M | −$28.9M | −$28.4M | −$39.5M | −$47.3M | −$62.3M |
| Capital expenditure | $9.00K | — | — | — | — | — | — | — | — | — |
| Free cash flow | −$4.93M | — | — | — | — | — | — | — | — | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$20.5M | — | −$18.0M | −$24.7M | −$19.1M | — | −$21.2M | −$22.9M |
| Net income | $77.0M | −$44.6M | −$6.50M | −$11.2M | −$17.5M | −$10.4M | −$39.0M | −$31.6M |
| EPS (diluted) | −$0.28 | $1.19 | −$0.08 | −$0.13 | −$0.21 | −$0.10 | −$0.33 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.75M | $20.5M | $8.50M | $5.74M | $3.67M | $22.8M | $6.15M | $6.80M |
| Total assets | $114.6M | $177.4M | $161.3M | $144.9M | $129.9M | $169.0M | $146.7M | $126.1M |
| Total liabilities | $38.5M | $59.3M | $46.7M | $38.9M | $38.8M | $32.2M | $46.2M | $54.1M |
| Shareholders' equity | $20.4M | $62.4M | $58.9M | $50.3M | $35.4M | $81.1M | $44.8M | $33.0M |
| Cash flow | ||||||||
| Operating cash flow | −$11.8M | −$19.0M | −$16.1M | −$17.7M | −$14.5M | −$14.1M | −$22.6M | −$22.7M |
From Eledon Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Eledon Pharmaceuticals Inc
- Headquarters
- Irvine, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International